Krystal Biotech Inc (KRYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.05B
Last updated: Nov 17, 2026 at 4:20 PM ET
Krystal Biotech Inc (KRYS) Statistics
Krystal Biotech (KRYS) has a market cap of $9.05B and an enterprise value of $8.58B. It kept 47.91% of revenue as net income over the last 12 months. Revenue grew 25.96% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 5.12% below the market cap, as cash exceeds debt.
| Market Cap | $9.05B |
|---|---|
| Enterprise Value | $8.58B |
| Latest price (Nov 17, 2026) | $297.90 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 18.8x and 6.1x.
| P/E Ratio | 40.4x |
|---|---|
| Forward P/E | 38.0x |
| P/S Ratio | 18.8x |
| Forward P/S | 18.2x |
| P/B Ratio | 6.1x |
| P/FCF Ratio | 28.4x |
| P/OCF Ratio | 27.9x |
| PEG Ratio | 0.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 35.7x EBITDA and 27.0x free cash flow.
| EV / Earnings | 38.1x |
|---|---|
| EV / Sales | 18.3x |
| EV / EBITDA | 35.7x |
| EV / FCF | 27.0x |
Price Statistics
The stock is up 48.05% over 52 weeks and trades 8.50% below its 50-day average.
| Beta (1Y) | 0.76 |
|---|---|
| 52-Week Change | +48.05% |
| 1-Month Change | -5.90% |
| 3-Month Change | -10.49% |
| 6-Month Change | +2.11% |
| 5-Year Change | +563.39% |
| Total Return (1Y) | +48.05% |
| Total Return (3Y CAGR) | +41.98% |
| Total Return (5Y CAGR) | +42.90% |
| Return vs SPY (1Y) | +33.94% |
| Max Drawdown (1Y) | -21.75% |
| Max Drawdown (3Y) | -42.26% |
| Sharpe Ratio (1Y) | 0.96 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $325.56 |
| 200-Day Average | $309.80 |
| 52-Week Range | $203.18 to $382.54 |
| RSI (14 Days) | 39.1 |
| Average Volume (20 Days) | 315.85K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.89x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.89x |
|---|---|
| Quick Ratio | 7.53x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 15.68% over the last 12 months, against a 5-year average of -2.18%.
| Return on Equity (ROE) | 15.68% |
|---|---|
| Return on Assets (ROA) | 14.20% |
| ROE (5Y Average) | -2.18% |
| ROA (5Y Average) | -2.21% |
| ROIC (5Y Average) | 13.23% |
| Asset Turnover | 0.33x |
| Inventory Turnover | 0.56x |
| Receivables Turnover | 3.46x |
| Cash Conversion Cycle | 160 days |
Taxes
Income tax took 12.99% of pretax income over the last 12 months.
| Income Tax (TTM) | $33.63M |
|---|---|
| Effective Tax Rate | 12.99% |
Scores
KRYS has an Altman Z-Score of 36.86, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 36.86 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $470.02M over the last 12 months.
| Revenue | $470.02M |
|---|---|
| Revenue Growth (YoY) | +25.96% |
| Gross Profit | $443.12M |
| Operating Income | $227.69M |
| Pretax Income | $258.80M |
| Net Income | $225.17M |
| Reported EPS (TTM) | $7.37 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.57% of the $1.59B in total assets.
| Cash and Equivalents | $462.84M |
|---|---|
| Total Debt | $0 |
| Net Cash | $462.84M |
| Net Cash Per Share | $15.63 |
| Working Capital | $979.62M |
| Shareholder Equity | $1.44B |
| Book Value Per Share | $48.48 |
| Total Assets | $1.59B |
| Total Liabilities | $150.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $13.85M of capital spending, operating cash flow left $310.08M of free cash flow.
| Operating Cash Flow | $323.93M |
|---|---|
| Capital Expenditures | $13.85M |
| Free Cash Flow | $310.08M |
| FCF Per Share | $10.48 |
| Depreciation and Amortization | $6.60M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 48.44%.
| Gross Margin | 94.27% |
|---|---|
| Operating Margin | 48.44% |
| Pretax Margin | 55.06% |
| Net Margin | 47.91% |
| FCF Margin | 65.97% |
Growth
| Book Value Per Share Growth (2Y CAGR) | +22.76% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +22.76% |
Dividends and Yields
KRYS does not pay a dividend. Its free cash flow yield is 3.52%.
| Earnings Yield | 2.48% |
|---|---|
| FCF Yield | 3.52% |
| Shareholder Yield | 0.00% |
Peer Position
Against 3 similar companies, KRYS has the 2nd highest P/E.
P/E RatioPeer median 39.5x
P/S RatioPeer median 15.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +61.04%
| P/E Ratio | 40.4x vs 39.5x median |
|---|---|
| P/S Ratio | 18.8x vs 15.9x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +25.96% vs +61.04% median |
Analyst Forecast
Consensus estimates put revenue growth at 27.73% and EPS growth at 16.07% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +27.73% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +16.07% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KRYS
What is KRYS's market cap?
Krystal Biotech has a market cap of $9.05B. Its enterprise value, which adds debt and subtracts cash, is $8.58B.
What is KRYS's P/E ratio?
Krystal Biotech has a trailing P/E ratio of 40.4x and a forward P/E of 38.0x.
How many shares of KRYS are outstanding?
Krystal Biotech has 29.61M shares outstanding. The count is up 2.27% from a year earlier.
Does KRYS pay a dividend?
No. Krystal Biotech does not pay a dividend.
How much debt does KRYS have?
Krystal Biotech has $0 of total debt and $462.84M of cash and equivalents, a net cash position of $462.84M.
KRYS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors